The global Stable Angina Management Market is expected to garner a market value of USD 11 Billion in 2023 and is expected to accumulate a market value of USD 25.1 Billion by registering a CAGR of 8.6% in the forecast period 2023 to 2033. The market for Stable Angina Management registered a CAGR of 5.2% in the historical period 2018 to 2022.
Pharmaceutical products commonly used for the treatment of stable angina include antiplatelet agents, such as aspirin and clopidogrel, and nitroglycerin, which helps to relax and widen blood vessels. Beta-blockers, calcium channel blockers, and ACE inhibitors may also be prescribed to manage stable angina.
Medical devices used for the management of stable angina include stents, which are small mesh tubes that are inserted into narrowed or blocked arteries to improve blood flow, and coronary artery bypass surgery (CABG), which involves rerouting blood flow around a blocked or narrowed artery.
The stable angina management market is driven by factors such as the growing prevalence of cardiovascular diseases, increasing adoption of advanced medical technologies, and rising healthcare expenditure. However, the market may face challenges such as the availability of alternative treatment options, high cost of some treatments, and limited access to healthcare in certain regions.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 11 Billion |
| Anticipated Forecast Value (2033) | USD 25.1 Billion |
| Projected Growth Rate (2023 to 2033) | 8.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Stable Angina Management reflected a value of 5.2% during the historical period, 2018 to 2022. The stable angina management market is expected to grow in the coming years due to various factors such as the rising prevalence of cardiovascular diseases, increasing demand for effective treatment options, and the adoption of advanced medical technologies.
The increasing prevalence of cardiovascular diseases and the growing geriatric population are expected to be the major driving factors for the market's growth. Moreover, the increasing adoption of innovative technologies such as drug-eluting stents, bioresorbable stents, and optical coherence tomography (OCT) for the diagnosis and treatment of stable angina is expected to drive market growth. The increasing demand for minimally invasive procedures is also expected to drive the market's growth as they offer less discomfort, shorter recovery times, and lower healthcare costs compared to traditional open-heart surgeries.
Overall, the market for Stable Angina Management is expected to register a CAGR of 8.6% in the forecast period 2023 to 2033.
Increasing Prevalence of Cardiovascular Diseases to Push Market Growth
The rising prevalence of cardiovascular diseases is expected to be one of the major drivers pushing the growth of the stable angina management market. Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels, and they are among the leading causes of death and disability worldwide. Stable angina is one of the most common forms of CVDs.
According to a report by the World Health Organization (WHO), CVDs are the leading cause of death globally, with an estimated 17.9 million deaths annually. The report also highlights that four out of five CVD deaths are due to heart attacks and strokes, which are often caused by a blockage that prevents blood flow to the heart or brain.
As the prevalence of CVDs continues to rise globally, the demand for effective treatment options for stable angina is also expected to increase. This is likely to drive the growth of the stable angina management market, as more patients seek medical interventions to manage their condition.
Moreover, the increasing incidence of risk factors for CVDs, such as high blood pressure, high cholesterol, obesity, and diabetes, is also contributing to the rise in CVDs. This is expected to further increase the demand for stable angina management products and services.
Overall, the rising prevalence of CVDs, along with increasing awareness and a growing demand for effective treatment options, is expected to push the growth of the stable angina management market in the coming years.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The high cost of treatment is a major challenge for the stable angina management market. The cost of diagnostic tests, medications, and procedures can be prohibitively expensive, especially for patients in developing countries. This can limit access to treatment options and hinder market growth.
The regulatory environment can also pose challenges to the stable angina management market. The approval process for new medical devices and treatments can be lengthy and expensive, and regulatory requirements can vary from country to country. Overall, while the stable angina management market has significant growth potential, it also faces several challenges that need to be addressed to ensure sustained growth and development.
Increasing awareness and diagnosis of the condition Shaping Landscape for Stable Angina Management in South & East Asia
One of the major drivers of the market growth in the region is the increasing prevalence of cardiovascular diseases, including stable angina. The rising incidence of risk factors such as obesity, high blood pressure, and diabetes, coupled with lifestyle changes, is contributing to the growing burden of cardiovascular diseases in the region.
Another factor contributing to the market growth is the increasing adoption of advanced medical technologies for the diagnosis and treatment of stable angina. The region has witnessed significant investments in the development of innovative medical devices and therapies, which are expected to drive market growth.
Moreover, the increasing healthcare expenditure by governments and private organizations in the region is expected to fuel the market's growth. Governments in the region are investing heavily in the development of healthcare infrastructure, which is expected to improve access to healthcare services for the population.
Overall, the stable angina management market in the South & East Asia region is expected to grow in the coming years, driven by the increasing prevalence of cardiovascular diseases and the adoption of advanced medical technologies. However, addressing the challenges and improving access to healthcare services and treatments will be critical for sustained market growth.
Increasing Focus on Technological advancements Shaping Landscape for Stable Angina Management in North America
The market for Stable Angina Management in North America is expected to grow due to several factors. The North American region has a high prevalence of cardiovascular diseases, including stable angina. According to the American Heart Association, cardiovascular diseases are the leading cause of death in the United States, with approximately 18.6 million adults diagnosed with coronary heart disease. The high prevalence of cardiovascular diseases is expected to drive the demand for stable angina management products and services in the region.
Secondly, the North American region is at the forefront of technological advancements in the healthcare sector. The development of advanced medical devices and therapies, such as drug-eluting stents, implantable cardioverter-defibrillators, and transcatheter aortic valve replacement (TAVR), has improved the diagnosis and treatment of stable angina. These advancements are expected to drive market growth in the region.
North America has one of the highest healthcare expenditures in the world. According to the Centers for Medicare & Medicaid Services (CMS), national health expenditures in the United States reached USD 3.8 trillion in 2019, accounting for 17.7% of the country's GDP. The high healthcare expenditure is expected to drive market growth as it improves access to healthcare services and treatments for patients with stable angina.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospital pharmacies segment to hold a significant share and push market growth
Hospital pharmacies are the primary distribution channels for stable angina management products and services. They have access to a wide range of products, including prescription drugs, medical devices, and surgical instruments, and they are well-equipped to handle complex patient cases. In addition, hospital pharmacies have the advantage of being able to provide patients with a range of healthcare services, including consultation with healthcare professionals, medication counseling, and monitoring of medication adherence.
Moreover, the hospital pharmacies segment is expected to grow due to the increasing number of hospital admissions for cardiovascular diseases, including stable angina. Hospitals are the primary point of care for patients with cardiovascular diseases, and they play a critical role in managing the disease and preventing complications. As a result, hospital pharmacies are likely to account for a significant share of the stable angina management market.
Key players in the market include companies such as Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc. along with healthcare providers and technology companies among other global players.
Corzyna is a new medication that has been found to decrease the occurrence of angina attacks when used with first-line agents like beta-blockers and calcium channel blockers, as compared to the use of first-line therapies alone. In addition, for those who are intolerant to first-line therapy, Corzyna can be added to lower the dose of first-line therapy, thereby reducing the risk of undesirable side effects such as low blood pressure or heart rate.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 11 Billion |
| Market Value in 2033 | USD 25.1 Billion |
| Growth Rate | CAGR of 8.6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Distribution Channel, Drug Class, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, Malaysia, Singapore, China, India, Thailand, Rest of South Asia, Gulf Cooperation Council, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Competition Deep Dive; Abbott; AstraZeneca; Bayer AG; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; ALLERGAN; Gilead Sciences; Inc.; GlaxoSmithKline plc.; Novartis AG; Pfizer Inc. |
| Customization | Available Upon Request |
From 2018 to 2022, Stable Angina Management Market grew at a CAGR of 5.2%.
The global Stable Angina Management Market is expected to grow with a 8.6% CAGR during 2023 to 2033.
As of 2033, the Stable Angina Management Market is expected to reach USD 25.1 Billion
According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
North America is expected to possess 40% market share for the Stable Angina Management Market.
The market is valued at USD 11.0 billion in 2023.
Abbott, AstraZeneca, and Bayer AG are the key market players.
The market registered a CAGR of 5.2% from 2018 to 2022.
Rising cases of cardiovascular diseases globally boost the market growth.
The hospital pharmacies segment is likely to remain preferred through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Beta Blockers 5.2. Calcium Antagonists 5.3. Anti-coagulants 5.4. Anti-Platelets 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Online Pharmacies 6.2. Hospital Pharmacies 6.3. Retail Pharmacies 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia 7.5. East Asia 7.6. Oceania 7.7. Middle East & Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Abbott 17.2. AstraZeneca 17.3. Bayer AG 17.4. Bristol-Myers Squibb Company 17.5. F. Hoffmann-La Roche Ltd 17.6. ALLERGAN 17.7. Gilead Sciences, Inc. 17.8. GlaxoSmithKline plc. 17.9. Novartis AG 17.10. Pfizer Inc. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Stable Angina Management Market
